Vanguard Group’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$4.09M Sell
2,009,145
-19,815
-1% -$40.3K ﹤0.01% 3280
2025
Q1
$3.31M Buy
2,028,960
+355,372
+21% +$579K ﹤0.01% 3317
2024
Q4
$3.06M Sell
1,673,588
-124,372
-7% -$228K ﹤0.01% 3439
2024
Q3
$10.4M Buy
1,797,960
+216,389
+14% +$1.25M ﹤0.01% 2938
2024
Q2
$12.8M Sell
1,581,571
-12,814
-0.8% -$104K ﹤0.01% 2779
2024
Q1
$22.1M Sell
1,594,385
-52,787
-3% -$733K ﹤0.01% 2550
2023
Q4
$10.1M Sell
1,647,172
-25,731
-2% -$157K ﹤0.01% 2943
2023
Q3
$7.81M Buy
1,672,903
+579
+0% +$2.7K ﹤0.01% 3028
2023
Q2
$8.96M Buy
1,672,324
+150,265
+10% +$805K ﹤0.01% 3010
2023
Q1
$15M Buy
1,522,059
+101,851
+7% +$1M ﹤0.01% 2740
2022
Q4
$26.6M Buy
1,420,208
+138,349
+11% +$2.59M ﹤0.01% 2489
2022
Q3
$26.5M Buy
1,281,859
+167,560
+15% +$3.47M ﹤0.01% 2506
2022
Q2
$23.1M Buy
1,114,299
+176,972
+19% +$3.67M ﹤0.01% 2570
2022
Q1
$40.4M Buy
937,327
+17,384
+2% +$749K ﹤0.01% 2409
2021
Q4
$55.1M Buy
919,943
+6,894
+0.8% +$413K ﹤0.01% 2296
2021
Q3
$78.4M Buy
913,049
+689
+0.1% +$59.2K ﹤0.01% 2115
2021
Q2
$101M Sell
912,360
-45,082
-5% -$5.01M ﹤0.01% 2000
2021
Q1
$107M Buy
957,442
+191,972
+25% +$21.4M ﹤0.01% 1915
2020
Q4
$81.3M Sell
765,470
-13,717
-2% -$1.46M ﹤0.01% 1941
2020
Q3
$108M Sell
779,187
-19,587
-2% -$2.73M ﹤0.01% 1649
2020
Q2
$258M Buy
798,774
+332,598
+71% +$108M 0.01% 1109
2020
Q1
$41.6M Buy
466,176
+45,143
+11% +$4.03M ﹤0.01% 1960
2019
Q4
$16.7M Sell
421,033
-4,970
-1% -$197K ﹤0.01% 2618
2019
Q3
$10.5M Buy
426,003
+20,986
+5% +$516K ﹤0.01% 2791
2019
Q2
$14.3M Buy
405,017
+2,918
+0.7% +$103K ﹤0.01% 2672
2019
Q1
$18M Buy
402,099
+23,173
+6% +$1.04M ﹤0.01% 2553
2018
Q4
$18.2M Buy
378,926
+25,311
+7% +$1.21M ﹤0.01% 2491
2018
Q3
$23.6M Buy
353,615
+15,371
+5% +$1.03M ﹤0.01% 2507
2018
Q2
$15.9M Buy
338,244
+12,509
+4% +$588K ﹤0.01% 2673
2018
Q1
$18.4M Buy
325,735
+1,997
+0.6% +$113K ﹤0.01% 2533
2017
Q4
$16M Buy
323,738
+8,734
+3% +$433K ﹤0.01% 2593
2017
Q3
$24M Buy
315,004
+46,069
+17% +$3.51M ﹤0.01% 2402
2017
Q2
$25.3M Buy
268,935
+10,764
+4% +$1.01M ﹤0.01% 2358
2017
Q1
$20.5M Buy
258,171
+18,905
+8% +$1.5M ﹤0.01% 2435
2016
Q4
$19.9M Buy
239,266
+4,957
+2% +$413K ﹤0.01% 2423
2016
Q3
$26.2M Buy
234,309
+1,462
+0.6% +$164K ﹤0.01% 2245
2016
Q2
$25.8M Buy
232,847
+9,754
+4% +$1.08M ﹤0.01% 2216
2016
Q1
$23.3M Buy
223,093
+16,428
+8% +$1.72M ﹤0.01% 2233
2015
Q4
$16.7M Buy
206,665
+2,833
+1% +$228K ﹤0.01% 2385
2015
Q3
$14.1M Buy
203,832
+13,124
+7% +$910K ﹤0.01% 2434
2015
Q2
$18.7M Buy
190,708
+22,481
+13% +$2.2M ﹤0.01% 2389
2015
Q1
$16.5M Buy
168,227
+7,288
+5% +$714K ﹤0.01% 2406
2014
Q4
$17.7M Buy
160,939
+15,800
+11% +$1.74M ﹤0.01% 2286
2014
Q3
$17.2M Buy
145,139
+5,269
+4% +$623K ﹤0.01% 2260
2014
Q2
$18.1M Buy
139,870
+21,587
+18% +$2.8M ﹤0.01% 2250
2014
Q1
$18.9M Buy
118,283
+34,411
+41% +$5.5M ﹤0.01% 2210
2013
Q4
$11.7M Buy
83,872
+7,151
+9% +$995K ﹤0.01% 2393
2013
Q3
$7.62M Buy
76,721
+4,429
+6% +$440K ﹤0.01% 2523
2013
Q2
$2.76M Buy
+72,292
New +$2.76M ﹤0.01% 2952